A new obesity drug combining four hormones may outperform Wegovy and Mounjaro. Learn what it means for health, science, and investors.

A federal judge in Texas has upheld the FDA’s decision to remove GLP-1 drugs, including Novo Nordisk’s Ozempic and Wegovy, from its drug shortage list, rejecting a bid by compounding pharmacies to ...

Variants of obesity-related genes influence how much weight patients lose on specific weight loss drugs like liraglutide, two studies report.

Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a ...

In a phase 3 study (ESSENCE trial), weekly 2·4 mg subcutaneous semaglutide resulted in significantly greater ... Given the emerging role of GLP-1 receptor agonists in liver diseases, logically the ...

Metabolic dysfunction–associated steatohepatitis (MASH) is a form of liver disease that can progress ... to evaluate the GLP-1 receptor agonist semaglutide in patients with MASH and stage ...

The ability to not just halt but potentially reverse this scarring process could transform how we approach advanced liver disease treatment. Participants receiving semaglutide experienced an ...

One study found that semaglutide helps to improve liver health in people with metabolic dysfunction-associated steatohepatitis, a serious form of fatty liver disease. The use of semaglutide ...

Share on Pinterest Semaglutide may be effective in treating a form of fatty liver disease, new research shows. Steve Christo – Corbis/Getty Images Semaglutide is a GLP-1 agonist medication that ...